Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Rhabdomyosarcoma 5Prostatic Neoplasms 5Sarcoma, Synovial 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma, Ewing 2Neoplasm Metastasis 2Lung Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1

Interventions

Carboplatin 171Paclitaxel 129Radiotherapy 119Cisplatin 109Docetaxel 93Gemcitabine 81Erlotinib Hydrochloride 80Pemetrexed 78Bevacizumab 56Etoposide 41pembrolizumab 36Gefitinib 32Vinorelbine 31Topotecan 30Surveys and Questionnaires 29Irinotecan 28Radiosurgery 21Nivolumab 20Drug Therapy 20Magnetic Resonance Spectroscopy 18Cetuximab 18durvalumab 17Early Intervention, Educational 17Blood Specimen Collection 17Surgical Procedures, Operative 16Cyclophosphamide 16Celecoxib 15Ipilimumab 14Immunohistochemistry 14Filgrastim 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lung Neoplasms × cixutumumab × Clear all
NCT01232452 2019-09-20

A Study in Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
172 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01263782 2019-05-15

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
64 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡